Meet the management of Nicox, an international ophthalmology company developing innovative solutions for maintaining vision and improving eye health. Nicox currently has two products approved for commercialization in the United States: VYZULTATM (ophthalmic solution of latanoprostene bunod), 0.024% for the reduction of intraocular pressure in patients with open angle glaucoma or ocular hypertension, marketed since December 2017 by partner Bausch + Lomb and ZERVIATETM (cetirizine ophthalmic solution), 0.24% for eye pruritus associated with allergic conjunctivitis whose commercial launch in the United States is planned for the end of 2018 by partner Eyevance Pharmaceuticals. Its product portfolio also includes drug candidates at a clinical development stage from both its proprietary research platform of nitric oxide (NO) donor compounds and existing, clinically and commercially validated molecules.
Monday, March 5th, 2018
BEDFORD Hotel 17, rue de l’Arcade – 75008 Paris
6:45 p.m. OPENING
7 p.m. Meeting followed by a discussion with Mr Michele Garufi, CEO
– Company Presentation
– Research platform and technological innovations
– Portfolio of marketed and developing products
– Targeted markets
– Partnerships and commercial agreements
– Financial situation
– Next steps and perspectives
8.30 p.m. Cocktail, discussions with Mr Garufi and networking
